摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

间氨基苯磺酰苯胺 | 80-21-7

中文名称
间氨基苯磺酰苯胺
中文别名
3-[(4-氨基苯基)磺酰基]苯胺
英文名称
3-amino-N-phenylbenzenesulfonamide
英文别名
1-aminobenzene-3-sulphonic acid phenylamide
间氨基苯磺酰苯胺化学式
CAS
80-21-7
化学式
C12H12N2O2S
mdl
MFCD00035928
分子量
248.305
InChiKey
SOZFVONLAQIHRF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    >37.2 [ug/mL]

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    80.6
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2935009090

SDS

SDS:72a0468814df24536a58defb3f23476e
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Amino-N-phenylbenzenesulfonamide
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-N-phenylbenzenesulfonamide
CAS number: 80-21-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H12N2O2S
Molecular weight: 248.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

染料中间体。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    间氨基苯磺酰苯胺盐酸硫酸sodium carbonatesodium hydrogensulfite 、 sodium nitrite 作用下, 生成 3-Hydrazino-N-phenyl-benzenesulfonamide
    参考文献:
    名称:
    Lisitsyn, V. N.; Sazonchik, O. B., Russian Journal of Organic Chemistry, 1994, vol. 30, # 5.2, p. 780 - 784
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-硝基-n-苯基苯磺酰胺铁粉氯化铵 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以90%的产率得到间氨基苯磺酰苯胺
    参考文献:
    名称:
    强效和特异性锥硫酮还原酶抑制剂的优化:一种基于结构的药物发现方法
    摘要:
    利什曼原虫属 每年负责多达 100 万个新病例。目前针对利什曼原虫的治疗手段在很大程度上是不足的,迫切需要更好的药物。锥虫硫酮还原酶 (TR) 代表了一种可药用靶标,因为它对寄生虫至关重要,而不为人类宿主所共有。在这里,我们报告了通过涉及 X 射线晶体学、合成、构效关系 (SAR) 研究、分子建模和体外表型测定的协同努力实现的新型强效和选择性Li TR 抑制剂的优化。5-硝基噻吩-2-羧酰胺3、6e和8是本研究中鉴定的最有效和选择性的TR抑制剂之一。图 6e和8显示了与 SI > 50 耦合的低微摩尔范围内的利什曼杀灭活性。由于 TR 酶的结构相似性,我们的研究可以为使用 TR 抑制剂不仅针对利什曼病而且还针对其他锥虫科铺平道路。
    DOI:
    10.1021/acsinfecdis.2c00325
点击查看最新优质反应信息

文献信息

  • [EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2005123738A1
    公开(公告)日:2005-12-29
    The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.
    该发明涉及公式(I)中R1、R2、R3、R4、R5和p的化合物,其中这些参数在说明和权利要求中有定义,以及其药学上可接受的盐本身和作为药用活性物质,其制备方法,基于与该发明相符合的化合物的药物,以及它们的生产,以及在控制或预防上述疾病方面使用与该发明相符合的化合物,以及分别用于生产相应的药物。
  • 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
    申请人:Djung Far-Jine Jane
    公开号:US20070293494A1
    公开(公告)日:2007-12-20
    The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.
    本发明涉及2-芳基基-4-(杂环)氨基嘧啶抑制剂,这些抑制剂是蛋白激酶C-alpha (PKC-α)的抑制剂,因此能够抑制PKC-α。本发明的PKC-α抑制剂对于改善心肌细胞内循环非常重要,从而提高心肌的收缩和舒张性能,从而减缓心力衰竭的进展。本发明还涉及包含所述2-芳基基-4-(杂环)氨基嘧啶的组合物以及用于控制、减轻或以其他方式减缓心力衰竭进展的方法。
  • Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27
    作者:Thanigaimalai Pillaiyar、Francesca Rosato、Monika Wozniak、Jeremy Blavier、Maëlle Charles、Céline Laschet、Thales Kronenberger、Christa E. Müller、Julien Hanson
    DOI:10.1016/j.ejmech.2021.113777
    日期:2021.12
    2,4-dichloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (I, pEC50 6.34, Emax 100%). Here, we describe the synthesis and structure-activity relationships of a series of new derivatives and analogs of I. All products were evaluated for their ability to activate GPR27 in an arrestin recruitment assay. As a result, agonists were identified with a broad range of efficacies including partial and full agonists
    GPR27 与 GPR85 和 GPR173 一起属于三个受体的小亚家族,称为“大脑中表达的超保守受体”(SREB)。它被假定参与关键的生理过程,如神经元可塑性、能量代谢和胰腺 β 细胞胰岛素分泌和调节。最近,我们报道了第一个选择性 GPR27 激动剂,2,4-二-N- (4-( N-苯基磺酰基)苯基)苯甲酰胺 ( I , pEC 50 6.34, E max 100%)。在这里,我们描述了I的一系列新衍生物和类似物的合成和构效关系。. 在抑制蛋白募集测定中评估了所有产品激活 GPR27 的能力。结果,确定了具有广泛功效的激动剂,包括部分激动剂和完全激动剂,显示出比先导化合物I更高的功效。最有效的激动剂是 4-chloro-2,5-difluoro- N- (4-( N - phenylsulfamoyl)phenyl)benzamide ( 7y , pEC 50 6.85, E max
  • [EN] SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA<br/>[FR] INHIBITEURS DE SOX11 POUR TRAITER UN LYMPHOME À CELLULES DU MANTEAU
    申请人:ICAHN SCHOOL MED MOUNT SINAI
    公开号:WO2021257544A1
    公开(公告)日:2021-12-23
    Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.
    公开的是一些化合物,它们是SOX11的化学抑制剂。所公开的化合物在治疗多种癌症方面是有用的。
  • Synthesis and Anticandidal Activity of Azole-Containing Sulfonamides
    作者:Amjad M. Qandil、Mohammad A. Hassan、Nizar A. Al-Shar'i
    DOI:10.1002/ardp.200700125
    日期:2008.2
    aromatic ring. Secondary sulfonamides, 5l, 5m, and 5n showed activities that were proportional to their lipophilicity. The activities of N‐aryl‐substituted derivatives 5j, 5k, 5l, 5m, 5n, and 6j were also proportional to their lipophilicity. Halogenation enhanced the activity as a result of improvement of lipophilicity. The presence of two imidazole or triazole rings in the same compound did not show
    已经合成了 25 种含有一个咪唑或三唑环,或两个咪唑或三唑环的苯磺酰胺,并作为抗念珠菌剂进行了评估。活性最强的化合物为 5c、6b、6c、6e 和 17b,根据临床分离株的不同,MIC 值为 4.55-24.39 mM。将咪唑与三唑衍生物进行比较并没有显示出对活性的明显影响。考虑到含有 N-苄基的化合物具有额外的芳环,它们也没有显示出明确的活性证据。二级磺胺类药物 5l、5m 和 5n 显示出与其亲脂性成正比的活性。N-芳基取代衍生物5j、5k、5l、5m、5n和6j的活性也与其亲脂性成正比。作为亲脂性改善的结果,卤化增强了活性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫